Zonisamide
Product Images NDC 53217-301

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Zonisamide (NDC 53217-301). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Zonisamide Usp 1)

Image (Zonisamide Usp 1)
The text describes a table showing the median percentage reduction and percentage responders in all partial seizures for three studies. The studies compare the effectiveness of a drug called ZONEGRAN to a placebo. There are different numbers of participants in each study, and the reduction and responder percentages vary between studies and between ZONEGRAN and the placebo. The text indicates that there is a statistically significant difference between ZONEGRAN and the placebo in at least one of the studies.*
FDA Label Image

Image (Zonisamide Usp 2)

Image (Zonisamide Usp 2)
This is a table presenting the median percentage reduction in all partial seizures and percentage of responders for dose analyses in Study 1 using Zonisamide and Placebo. The study was an intent-to-treat analysis. The table shows median % reduction in partial seizures and % responders for three groups divided by doses administered (0-400 mg/day, 100 mg/day, and 200 mg/day) at different weeks. There are statistically significant differences compared to the placebo, and some of the differences are clinical.*
FDA Label Image

Image (Zonisamide Usp 3)

FDA Label Image

Image (Zonisamide Usp 4)

FDA Label Image

Image Description (Zonisamide Usp 5)

Image Description (Zonisamide Usp 5)
This appears to be a description of a medication called Zonisamide, USP, in 100mg capsules. It mentions a few different lots and package quantities, as well as information on the manufacturer Invagen Pharmaceuticals, based in Hauppauge, NY. However, without further context or information on the intended use or effects of the medication, it is difficult to provide more precise details.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.